Ligand Pharmaceuticals Incorporated

80.47 USD
-0.17 (-0.21%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Ligand Pharmaceuticals Incorporated stock is down -7.11% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.16% of the previous 18 June’s closed higher than May.

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae. The company also offers Rylaze, a recombinant erwinia asparaginase, and Nexterone, a captisol-enabled formulation of amiod